Slingshot members are tracking this event:

FDA Designates Immunomedics' (IMMU) IMMU-132 a Breakthrough Therapy for Treatment of Triple Negative Breast Cancer (TNBC)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Immu-132, Braekthrough Therapy Designation, Triple Negative Breast Cancer, Resistant To Therapy